Squarepoint Ops LLC Buys Shares of 38,188 Eagle Pharmaceuticals Inc (EGRX)

Squarepoint Ops LLC bought a new position in Eagle Pharmaceuticals Inc (NASDAQ:EGRX) during the 4th quarter, HoldingsChannel.com reports. The institutional investor bought 38,188 shares of the specialty pharmaceutical company’s stock, valued at approximately $1,539,000.

A number of other hedge funds and other institutional investors also recently modified their holdings of the business. LS Investment Advisors LLC boosted its stake in Eagle Pharmaceuticals by 97.9% during the fourth quarter. LS Investment Advisors LLC now owns 2,157 shares of the specialty pharmaceutical company’s stock valued at $87,000 after buying an additional 1,067 shares in the last quarter. Flinton Capital Management LLC boosted its stake in Eagle Pharmaceuticals by 23.9% during the fourth quarter. Flinton Capital Management LLC now owns 2,464 shares of the specialty pharmaceutical company’s stock valued at $99,000 after buying an additional 476 shares in the last quarter. Acadian Asset Management LLC boosted its stake in Eagle Pharmaceuticals by 82.1% during the fourth quarter. Acadian Asset Management LLC now owns 3,008 shares of the specialty pharmaceutical company’s stock valued at $121,000 after buying an additional 1,356 shares in the last quarter. Neuburgh Advisers LLC boosted its stake in Eagle Pharmaceuticals by 23.9% during the fourth quarter. Neuburgh Advisers LLC now owns 2,992 shares of the specialty pharmaceutical company’s stock valued at $121,000 after buying an additional 578 shares in the last quarter. Finally, Pacer Advisors Inc. boosted its stake in Eagle Pharmaceuticals by 175.4% during the third quarter. Pacer Advisors Inc. now owns 2,382 shares of the specialty pharmaceutical company’s stock valued at $165,000 after buying an additional 1,517 shares in the last quarter. 94.36% of the stock is currently owned by hedge funds and other institutional investors.

Several research analysts recently weighed in on the company. Zacks Investment Research raised Eagle Pharmaceuticals from a “hold” rating to a “buy” rating and set a $44.00 target price for the company in a research note on Thursday, February 14th. Mizuho increased their price target on Eagle Pharmaceuticals from $40.00 to $41.00 and gave the company a “neutral” rating in a research report on Friday, March 22nd. Cantor Fitzgerald reiterated a “hold” rating and issued a $58.00 price target on shares of Eagle Pharmaceuticals in a research report on Thursday, February 28th. ValuEngine upgraded Eagle Pharmaceuticals from a “sell” rating to a “hold” rating in a research report on Tuesday, March 19th. Finally, BidaskClub upgraded Eagle Pharmaceuticals from a “sell” rating to a “hold” rating in a research report on Saturday, February 23rd. Five investment analysts have rated the stock with a hold rating and three have assigned a buy rating to the company. The company presently has a consensus rating of “Hold” and a consensus target price of $63.67.

NASDAQ:EGRX opened at $50.18 on Tuesday. The company has a debt-to-equity ratio of 0.24, a current ratio of 4.13 and a quick ratio of 3.92. Eagle Pharmaceuticals Inc has a 1-year low of $36.03 and a 1-year high of $85.66. The firm has a market capitalization of $703.04 million, a P/E ratio of 24.01 and a beta of 1.72.

Eagle Pharmaceuticals (NASDAQ:EGRX) last released its quarterly earnings results on Thursday, February 28th. The specialty pharmaceutical company reported $1.20 earnings per share for the quarter, beating the Zacks’ consensus estimate of $1.16 by $0.04. Eagle Pharmaceuticals had a return on equity of 17.76% and a net margin of 14.96%. The business had revenue of $56.05 million during the quarter, compared to analyst estimates of $54.17 million. During the same quarter last year, the company posted $1.05 EPS. Eagle Pharmaceuticals’s revenue for the quarter was up 19.8% on a year-over-year basis. Research analysts expect that Eagle Pharmaceuticals Inc will post 3.43 EPS for the current fiscal year.

In related news, CEO Scott Tarriff sold 24,428 shares of the stock in a transaction on Friday, March 1st. The stock was sold at an average price of $51.17, for a total value of $1,249,980.76. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is available at the SEC website. Insiders sold a total of 86,082 shares of company stock valued at $3,746,371 in the last quarter. 28.20% of the stock is currently owned by corporate insiders.

TRADEMARK VIOLATION WARNING: “Squarepoint Ops LLC Buys Shares of 38,188 Eagle Pharmaceuticals Inc (EGRX)” was first reported by Sports Perspectives and is the property of of Sports Perspectives. If you are viewing this report on another publication, it was illegally copied and republished in violation of US and international copyright & trademark law. The correct version of this report can be accessed at https://sportsperspectives.com/2019/04/02/squarepoint-ops-llc-buys-shares-of-38188-eagle-pharmaceuticals-inc-egrx.html.

Eagle Pharmaceuticals Profile

Eagle Pharmaceuticals, Inc, a specialty pharmaceutical company, focuses on developing and commercializing injectable products primarily in the critical care and oncology areas in the United States. The company offers Argatroban, an anti-coagulant thrombin inhibitor for heparin-induced thrombocytopenia; Ryanodex for malignant hyperthermia; Bendeka for chronic lymphocytic leukemia (CLL) and indolent B-cell non-Hodgkin's lymphoma (NHL); and Belrapzo, a chemotherapeutic agent for CLL and Indolent NHL.

Read More: Capital gains and your 401(k) or IRA

Want to see what other hedge funds are holding EGRX? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Eagle Pharmaceuticals Inc (NASDAQ:EGRX).

Institutional Ownership by Quarter for Eagle Pharmaceuticals (NASDAQ:EGRX)

Receive News & Ratings for Eagle Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Eagle Pharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.